Related Experiment Videos
Tuberculosis in heart transplant recipients
M M Körner1, N Hirata, G Tenderich
1Heart Center Northrlune-Westphalia, University Hospital of Ruhr, University of Bochum, Bad Oeynhausen, Germany.
Chest
|February 1, 1997
Summary
Tuberculosis occurred in 1% of heart transplant recipients, often developing months post-transplant. Careful monitoring and treatment, especially with rifampicin, are crucial for patient survival.
Area of Science:
- Cardiology
- Infectious Diseases
- Transplantation Medicine
Background:
- Heart transplantation is a life-saving procedure for end-stage heart failure.
- Immunosuppression is essential post-transplant but increases infection risk.
- Tuberculosis (TB) is a significant opportunistic infection in immunocompromised patients.
Purpose of the Study:
- To determine the prevalence of tuberculosis in heart transplant recipients.
- To identify factors associated with tuberculosis development in this population.
- To assess patient survival rates following tuberculosis diagnosis post-heart transplant.
Main Methods:
- Retrospective review of 727 heart transplant recipients between March 1989 and February 1996.
- Analysis of patient records to identify tuberculosis cases, timing of diagnosis, and treatment regimens.
- Evaluation of immunosuppressive strategies and their potential impact on tuberculosis development.
Main Results:
- Tuberculosis was diagnosed in 7 (1%) of 727 heart transplant recipients.
- TB developed between 2.5 and 41 months post-transplant, with varied lesion sites (miliary, pulmonary, urogenital).
- Six patients are recovering well with multi-drug TB therapy; one patient died from miliary TB.
Conclusions:
- The prevalence of tuberculosis in heart transplant recipients is higher than in the general population.
- Maintaining a high clinical suspicion for TB in heart transplant recipients is recommended.
- Meticulous care during TB treatment, particularly concerning rifampicin use due to its interaction with cyclosporine, is vital.